BOSTON, Sept. 30, 2024 -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today...
News & Events
Upcoming Events.
10.29.2024
Art Pappas will be participating on a panel at BioFuture New York on October 29th.
Art Pappas will be participating on a panel titled "The Financial…
Location
New York, NY
07.01.2022
Biomedical Advanced Research & Development Authority (BARDA) Accelerator Network Collaborative Virtual Series
Art Pappas will be participating in BARDA's Accelerator Network C…
Location
virtual
09.28.2022
Women in Agribusiness Summit 2022
Karen LeVert will be participating on a panel titled "Ag Innovati…
Location
Dallas, TX
11.02.2022
Life Sciences Summit
Peter Young will be participating on a panel titled "Investor and…
Location
(virtual)
11.10.2022
The Future of the Life Sciences Industry in Wilmington, NC
Art Pappas will be participating on a panel titled "How does Wilm…
Location
Wilmington, NC
11.10.2022
NC Global Advantage Forum
Karent LeVert will be speaking at the NC Global Advantage Forum o…
Location
Research Triange Park, NC
01.10.2023
Biotech Showcase 2023
Elizabeth Kelly will be participating on a panel titled "Finance …
Location
San Francisco, CA
01.11.2023
Biotech Showcase 2023
Peter Young will be participating on a panel titled "Early Seed F…
Location
San Francisco, CA
05.11.2023
Research Triangle Partnership's 2023 State of the Region Event
Karen LeVert will be providing an overview of Ag Tech Opportuniti…
Location
Raleigh, NC
;
In honor of National Liver Awareness Month, we would like to share some important but jarring statistics compiled by the @HepBFoundation. HBV is not only a chronic liver condition, but it is also one of the primary causes of liver cancer.
Learn more about the work we are doing…
Pappas Capital is pleased to announce our newest portfolio company Aktis Oncology!
AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS...
/PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel ...
www.prnewswire.com
Glycomine is pleased to share that we have received FDA Fast Track Designation for GLM101, a potential treatment in #clinicaltrials for #PMM2CDG, a rare genetic disorder of glycosylation.
Read the release for more: https://www.glycomine.com/glycomine-receives-fda-fast-track-designation-for-glm101-for-the-treatment-of-pmm2-cdg/
#CDGresearch #RareDisease #FastTrack
Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support Research Excellence in Lysosomal Sto...
Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support Research Excellence...
Applications for the independently assessed, expert-led Research Grant Initiative, Find For Rare, are open from today, ...
prn.to
